叶酸补充剂用于外围神经病变:系统性审查
Ana Carolina Alves Maues1, Mònica Gemma Moren Abat1, María Benlloch2
1OPKO Health Spain S.L.U., Palol de Revardit, 17843 Girona, Spain.
Nutrients
|October 29, 2025
概括
叶酸补充对外围神经病变 (PN) 具有显著的益处,改善症状和神经结构,具有强大的安全性. 这项研究强调了叶酸.
科学领域:
- 神经学 神经学
- 营养科学 营养科学
- 临床研究 临床研究
背景情况:
- 周围神经病变 (PN) 是一个不断增长的全球健康问题,特别是糖尿病PN.
- 实验数据表明,叶酸可以通过髓支持,减少氧化应激和增强神经营养因子来保护神经.
- 缺乏关于叶酸在PN管理中的有效性和安全性的临床证据.
研究的目的:
- 评估叶酸在治疗外围神经病变中的有效性和安全性.
- 评估叶酸对PN患者疼痛,症状,神经结构和生物标志物的影响.
主要方法:
- 在PubMed,Scopus,Web of Science和Cochrane图书馆进行了全面的文献搜索,截至2025年7月.
- 收集了评估叶酸用于PN管理的研究.
- 结果包括疼痛评分,症状缓解,NTSS,ENFD,生物标志物和不良事件.
主要成果:
- 叶酸补充导致显著的疼痛减轻 (3 分) 和高症状解决率 (87.5%).
- 观察到表皮神经纤维密度 (ENFD) 的客观改善 (增加高达97%).
- 叶酸表现出了极好的安全性,副作用最小,并降低了同类半氨酸和hs-CRP水平.
结论:
- 叶酸显示了对外围神经病变的有希望的症状和结构性益处.
- 叶酸补充剂对关键生物标志物产生积极影响,并表现出良好的安全性.
- 进一步的临床评估支持叶酸作为PN的潜在治疗剂.
相关概念视频
01:26Peripheral Artery Disease IV: Nursing Management
342
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
342
01:24Parkinson's Disease: Treatment
970
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
970
01:30Peripheral Artery Disease I: Introduction
302
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
302
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
346
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
346
01:22Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806
01:29Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K